Article
NCCN Recommends Only One Test for Breast Cancer, Says Expert
According to Dr Amy Cyr from the Siteman Cancer Center at Washington University in St. Louis, Missouri, while Oncotype DX is both prognostic and predictive, none of the other tests currently available have shown both capabilities.
The National Comprehensive Cancer Network (NCCN) only endorses one genomic test for use in patients with early-stage breast cancer, according to a presenter here at the NCCN 20th Annual Conference.
Oncotype DX, a 21-gene assay from Genomic Health, has won that honor, said presenter Amy Cyr, MD, from the Siteman Cancer Center at Washington University in St. Louis, Missouri.
In short, Oncotype DX is both prognostic and predictive.
The ability to predict response to treatment "is what, so far, makes this test stand out," she said.
Link to the report on Medscape:
The test serves two functions. In addition to providing a prognosis, the test has "some prediction capabilities in terms of therapy; it actually predicts a response to chemotherapy, compared with no chemotherapy," she explained.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
